Actively Recruiting
Hemp Seed Awareness
Led by University Hospital, Angers · Updated on 2024-06-11
600
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hemp is a plant of the Cannabaceae family. Cannabis sativa, derived from female flowers, is the first illicit substance used by adolescents and is a major public health problem. Its psycho-active effects come from tetrahydrocannabinol (THC). Unlike recreational cannabis, industrial hemp derived from cannabis sativa has a high level of cannabidiol (CBD) but a negligible level of tetrahydrocannabinol. Its seeds are now consumed in various forms and generate increasing interest. Seeds have many nutritional benefits. It seems important to take an interest in hemp, given the recent expansion of medical cannabis and the increasing use of cannabis for recreational purposes. It is incriminated in various allergies (contact dermatitis, asthma, rhinoconjunctivitis) but also in the occurrence of anaphylaxis to certain foods by cross-allergy in atopic subjects, in association with an Lipid-Transfer Proteins (LTP protein), present in the flower of Cannabis sativa. Unlike the allergy to recreational cannabis, the allergenicity of hemp seeds is little studied. Hemp seed can cause severe anaphylactic reactions. In all reported cases, the prick-tests were positive for the seeds. Often, patients had never been in contact with hemp seeds but had already been exposed to cannabis by respiratory or manual routes. The investigators hypothesize that sensitization by the skin or respiratory route (cannabis smokers, passive exposure to cannabis, workers exposed to hemp, etc.) could lead to the development of a food allergy to hemp seed.
CONDITIONS
Official Title
Hemp Seed Awareness
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (18 years or older)
- Referred to the Allergology Unit of the Hospital of Angers for prick-tests either in consultation or hospitalization
- Affiliated with or beneficiary of a social security scheme
- Able to provide informed consent
You will not qualify if you...
- Pregnant women or women who have recently given birth
- Persons deprived of liberty by administrative or judicial decision
- Persons receiving psychiatric care under duress
- Adults under legal protection measures
- Individuals unable to express consent
- People who cannot understand the French language
- Patients whose skin condition or medication use prevents interpretation of prick-tests (e.g., unable to stop antihistamines or severe eczema)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MORISSET Martine
Angers, France
Actively Recruiting
Research Team
M
Martine MORISSET
CONTACT
D
DRCI Promotion Interne
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here